<DOC>
	<DOCNO>NCT01859754</DOCNO>
	<brief_summary>Study Design : This 2 arm non-interventional trial compare occurrence adverse drug reaction Octagam 5 % market IVIG infusion treatment .</brief_summary>
	<brief_title>Octagam 5 % Versus Comparator Post Marketing Trial</brief_title>
	<detailed_description>This Post Marketing Study prospective , 2-armed , multicenter , non-interventional study . Patients either administered brand IGIV therapy order prescribe physician , patient issue unspecified generic prescription IGIV therapy , octagam® 5 % another brand IGIV therapy provide Investigator accord federal , state local regulation good clinical practice ( GCP ) guideline . The primary objective ass evaluate safety profile octagam® 5 % administration routine clinical use label indication , special emphasis occurrence TEEs . The incidence TEEs patient receive octagam® 5 % compare incidence rate matching concurrent control group patient receive IGIVs routine clinical use .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>1 . Male female patient age 18 year . 2 . Patients confirm diagnosis Primary Humoral Immunodeficiency ( PI ) state World Health Organization require immunoglobulinreplacement therapy due hypogammaglobulinemia agammaglobulinemia . 3 . Patients regular treatment ( every 3 4 week ) low dose IGIV ( 1 g/kg ) period least 6 month without change brand . 1 . Patients history TEEs within previous 24 month . 2 . Patients regular treatment frequency every 3 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Primary Immune Deficiency Syndrome</keyword>
	<keyword>Primary immunodeficiency Disease ( PIDD )</keyword>
	<keyword>PID</keyword>
</DOC>